34 unknown. 34 Phase 2, 13 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Unknown 34 |
| Phase 3 | 13 | Unknown 13 |
| Phase 1 | 6 | Unknown 6 |
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer Hydroxychloroquine, Sacituzumab Govitecan, Trastuzumab Deruxtecan - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 120 | 2024-01-29 | 2024-03-25 |
| Tacrolimus for Thrombocytopenia in SS Hydroxychloroquine, Tacrolimus - Sjogren Syndrome With Other Organ Involvement | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 54 | 2023-02-01 | 2023-01-10 |
| Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients Hydroxychloroquine - Mastocytosis | Phase 2 / Phase 3 | Unknown | University Hospital, Toulouse | 30 | 2021-10-01 | 2021-10-20 |
| Hydroxychloroquine and Indapamide in SPMS Hydroxychloroquine Pill, Indapamide Pill - Multiple Sclerosis, Secondary Progressive | Phase 2 | Unknown | University of Calgary | 35 | 2021-10-01 | 2022-05-18 |
| Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19 Hydroxychloroquine Pill + Azithromycin Pill, SOC - Acute Respiratory Distress Syndrome, Covid19 | Phase 2 | Unknown | Maimónides Biomedical Research Institute of Córdoba | 132 | 2021-02-10 | 2021-07-08 |
| The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial) Ivermectin 0.6mg/kg/day, Ivermectin 1.0mg/kg/day, Placebo - Covid19 | Phase 2 / Phase 3 | Unknown | Corpometria Institute | 294 | 2021-01-25 | 2021-01-15 |
| Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19 Hydroxychloroquine with Azithromycin - Covid19 | Phase 2 / Phase 3 | Unknown | Coordinación de Investigación en Salud, Mexico | 105 | 2021-01-20 | 2021-08-04 |
| Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis hydroxychloroquine - SARS-CoV Infection | Phase 2 / Phase 3 | Unknown | Regional Center for Disease Control and Prevention, Jordan | 93 | 2020-10-27 | 2020-10-22 |
| Hydroxychloroquine for Treatment of Non-Severe COVID-19 Hydroxychloroquine tablets - Covid19 | Phase 2 | Unknown | Makerere University | 105 | 2020-09-18 | 2021-04-26 |
| International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Vitamin C, Hydroxychloroquine, Azithromycin - COVID19 | Phase 2 | Unknown | National Institute of Integrative Medicine, Australia | 200 | 2020-09-09 | 2020-09-11 |
| Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients Hydroxychloroquine - COVID 19 | Phase 2 / Phase 3 | Unknown | Hamad Medical Corporation | 500 | 2020-08-31 | 2020-08-11 |
| Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19 Hydroxychloroquine , Sofosbuvir, daclatasvir, Standard of care treatment - COVID-19 | Phase 2 / Phase 3 | Unknown | Cairo University | 100 | 2020-07-01 | 2020-06-25 |
| TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia Tofacitinib, Hydroxychloroquine - Pneumonitis, Interstitial, COVID-19 | Phase 2 | Unknown | Università Politecnica delle Marche | 116 | 2020-06-01 | 2020-05-15 |
| Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients Hydroxychloroquine/Azithromycine, Quinquina-Stevia/Azythromycin, 4Plants/Azythromycin - Covid19 | Phase 2 | Unknown | Institute for Research and Development of Medicinal and Food Plants of Guinea | 231 | 2020-06-01 | 2020-08-07 |
| Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19 Hydroxychloroquine plus Nitazoxanide, Standard care - COVID-19 | Phase 2 / Phase 3 | Unknown | Tanta University | 100 | 2020-05-01 | 2020-04-24 |
| Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 Hydroxychloroquine Sulfate 200 MG, Placebo - COVID 19 | Phase 2 | Unknown | Shaheed Zulfiqar Ali Bhutto Medical University | 200 | 2020-05-01 | 2020-05-19 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 Favipiravir, Standard of Care - COVID-19 | Phase 2 / Phase 3 | Unknown | Chromis LLC | 330 | 2020-04-23 | 2020-06-16 |
| Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care - COVID-19 | Phase 2 / Phase 3 | Unknown | Medical University of Vienna | 500 | 2020-04-16 | 2021-03-02 |
| Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 Hydroxychloroquine, Indomethacin, Zithromax Oral Product - COVID-19 | Phase 1 / Phase 2 | Unknown | Perseverance Research Center, LLC | 80 | 2020-04-16 | 2020-07-01 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 Levamisole Pill + Budesonide+Formoterol inhaler, Lopinavir/Ritonavir + hydoxychloroquine - COVID-19 | Phase 2 / Phase 3 | Unknown | Fasa University of Medical Sciences | 30 | 2020-04-04 | 2020-04-13 |
Showing 20 of 34. Sign in to see all of them.
COVID-19 (20) · Breast Neoplasms (2) · Severe Acute Respiratory Syndrome (2) · Acquired Immunodeficiency Syndrome (1) · Arthritis, Rheumatoid (1) · Carcinoma, Non-Small-Cell Lung (1) · Coronavirus Infections (1) · Disease Progression (1) · HIV Infections (1) · Hepatitis C, Chronic (1) · Hypoxia (1) · Inflammation (1) · Influenza, Human (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
National University Hospital, Singapore (2) · Cairo University (1) · Chromis LLC (1) · Coordinación de Investigación en Salud, Mexico (1) · Corpometria Institute (1) · Fasa University of Medical Sciences (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hadassah Medical Organization (1) · Hamad Medical Corporation (1) · Institute for Research and Development of Medicinal and Food Plants of Guinea (1) · Lynn McMahon (1) · Maimónides Biomedical Research Institute of Córdoba (1) · Makerere University (1)
China (2) · France (2) · Singapore (2) · Spain (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Guinea (1) · Iran (1) · Italy (1) · Mexico (1) · Netherlands (1) · Norway (1) · Pakistan (1)
Andreas Barratt-Due, MD, PhD (1) · Anne Margarita Dyrhol Riise, MD, Professor (1) · Bart Neyns, MD PhD (1) · Bernd Jilma, MD (1) · Elena Pavlikova, MD,PhD,Prof (1) · Fibhaa Syed, FRCP (1) · Flavio A Cadegiani, MD, PhD (1) · Francesco Pugliese, MD, PhD (1) · Inge Christoffer Olsen, PhD (1) · Jiang Quan, MD (1) · Jianli J Zhao, doctorate (1) · Kamal Okasha, MD, PhD (1) · Karin Ried, PhD (1) · Katerina Nezvalova-Henriksen, Pharm D, PhD (1) · Lawrence Lee, MD PhD (1)
PMID 12719004, PMID 15366588, PMID 15688692, PMID 16499032, PMID 17825510, PMID 20561931, PMID 21550310, PMID 24184265, PMID 26752081, PMID 26900129, PMID 31610260, PMID 31852507, PMID 31936284, PMID 32065348, PMID 32109013, PMID 32112977, PMID 32145363, PMID 32150360, PMID 32150748, PMID 32165426, PMID 32170559, PMID 32171076, PMID 32222346, PMID 32228825, PMID 32247925, PMID 32268923, PMID 32303365, PMID 32497319, PMID 32738928, PMID 32770240, PMID 33065103, PMID 33227231, PMID 34113254, PMID 34251903, PMID 34350582, PMID 34473343, PMID 34872511, PMID 35141170, PMID 35876699, PMID 35935856, PMID 36220325, PMID 36695483, PMID 39533001, PMID 40269760
2008 (1)